Ipsen Biopharm Limited

University of California

Merrimack Pharmaceuticals, Inc.

Akagera Medicines, Inc.

Other

Celator Pharmaceuticals, Inc.

Hermes Biosciences, Inc.

Research Corporation Technologies, Inc.

Sutter West Bay Hospitals

Sutter West Bay Hospital

Ipsen Biopharma Ltd.

California Pacific Medical Center

Dmitri B Kirpotin

James David Marks

Daryl C Drummond

Keelung Hong

Mark Eamon Hayes

Alexander Koshkaryev

Demetrios P Papahadjopoulos

Charles Noble

Suresh K Tipparaju

Weiwen Zheng

Christopher C Benz

John W Park

Bolin Geng

Daniel C Chan

Ozan Alkan

Andrew J O'Brien

Kevin Kesper

Antoine M Awad

Douglas J Moore

Thomas Joseph Wickham

Samuel V Agresta

Bart S Hendriks

Paul Bunn

Helen Lee

Daniel F Gaddy

Ross B Fulton

Paul A Bunn, Jr

Wei Wen Zheng

Wei-Wen Zheng

Francis C Szoka, Legal Representative

Demetrois Papahadjopoulos

Ulrik B Nielsen

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids are engineered with improved stability to oxidative degradation while in storage, while retaining high transfection activity or potency in cells. These lipids are designed to be biodegradable, thus improving the tolerability of nanoparticles formed with them in vivo. In addition, targeting of these nanoparticles in a highly specific manner to dendritic cells is provided for through inclusion of antibody conjugates directed against cell surface receptors.

Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.

Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and method of use thereof

The present disclosure provides compounds useful as ionizable cationic lipids. The ionizable cationic lipids are useful for preparing lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Cationic ionizable lipids were engineered with improved stability to oxidative degradation while in storage.

Ionizable cationic lipids

The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidylserine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs.

Irinotecan phospholipid liposomes with improved storage stability are provided, with related methods of treatment and manufacture. The irinotecan liposomes can have reduced formation of lyso-phosphatidylcholine (lyso-PC) during storage, and prior to administration to a patient.

Stabilizing camptothecin pharmaceutical compositions

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

The present invention provides liposome compositions containing substituted ammonium and/or polyanion, and optionally with a desired therapeutic or imaging entity. The present invention also provide methods of making the liposome compositions provided by the present invention.

Liposomes useful for drug delivery

Inhibiting ataxia telangiectasia and Rad3-related protein (ATR)

Growing community of inventors

Revere, MA, United States of America

Dmitri B Kirpotin